Skip to content
Theriva Biologics
  • ABOUT US
  • OUR SCIENCE
  • OUR PIPELINE
  • RESOURCES
  • CAREERS
  • INVESTORS
    • Overview
    • News
    • Events
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • FAQs
  • CONTACT
  • ABOUT US
  • OUR SCIENCE
  • OUR PIPELINE
  • RESOURCES
  • CAREERS
  • INVESTORS
    • Overview
    • News
    • Events
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • FAQs
  • CONTACT
Theriva Biologics
  • ABOUT US
  • OUR SCIENCE
  • OUR PIPELINE
  • RESOURCES
  • CAREERS
  • INVESTORS
    • Overview
    • News
    • Events
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • FAQs
  • CONTACT

Publications

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects

VCN-01 is an encouraging therapy against retinoblastoma

Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolyticadenovirus VCN-01

Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies

Recent Posts

  • Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Recent Comments

No comments to show.

Archives

  • April 2023

Categories

  • Uncategorized
Theriva Biologics

9605 Medical Center Dr.
Suite 270
Rockville, MD 20850
info@therivabio.com

Theriva

  • About Us
  • Our Science
  • Our Pipeline
  • Resources
  • Careers
  • Contact

Investors

  • Overview
  • News
  • Events
  • SEC Filings
  • Corporate Governance
  • Stock Information
  • FAQs
  • Privacy Policy
  • Disclaimer

© 2023 Theriva Biologics. All rights reserved.